Verification evidence is still being completed.
PDF / print export
Debiopharm
Lausanne, Switzerland
- Verified lead
- Frédéric Lévy
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer, Debiopharm International
- 2026 technical specialization
- Oncology Development, Specialty Therapeutics, and Partnered Clinical Strategy
- Review cycle
- May 2026
- Full address
- Forum apres-demain, Chemin Messidor 5-7, CH-1006 Lausanne, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Debiopharm management page confirming Frédéric Lévy as CEO.
- Editorial note
- Debiopharm adds a Swiss oncology-development node with a current official management disclosure and a visible partnering posture.
Oncology Development, Specialty Therapeutics, and Partnered Clinical Strategy
Clinical-development quality systems, Partnered drug-development governance
Debiopharm adds a Swiss oncology-development node with a current official management disclosure and a visible partnering posture.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Lausanne, Switzerland
Debiopharm
Oncology Development, Specialty Therapeutics, and Partnered Clinical Strategy · Clinical and partnered development
Verified 14 Mar 2026 · 3 sources
Clinical
Debiopharm adds a Swiss oncology-development node with a current official management disclosure and a visible partnering posture.
Contact & location
- Website
- debiopharm.com
- Company page
- Lead
- Frédéric Lévy (verified ↗)
- Compliance
- GLP
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Clinical and partnered development
- Capabilities
- Oncology Development · Partnered Clinical Strategy · Drug Development Governance
- Founded
- 1979
- Headcount
- 201-500
Clinical profileSTATUS: VERIFIED MARCH 2026
Frédéric Lévy
Chief Executive Officer, Debiopharm International
Full addressForum apres-demain, Chemin Messidor 5-7, CH-1006 Lausanne, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Debiopharm contact page listing Chemin Messidor 5-7, 1006 Lausanne.
Open sourceClinical and partnered development
Lausanne, Switzerland. Oncology Development, Specialty Therapeutics, and Partnered Clinical Strategy. Review completed on 14 Mar 2026.
Swiss and EU medicinal product oversight
Clinical-development quality systems, Partnered drug-development governance
Oncology Development, Specialty Therapeutics, and Partnered Clinical Strategy
Debiopharm adds a Swiss oncology-development node with a current official management disclosure and a visible partnering posture.
Editorial note
Debiopharm adds a Swiss oncology-development node with a current official management disclosure and a visible partnering posture.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Oncology Development
Partnered Clinical Strategy
Drug Development Governance
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development systems
Portfolio governance platforms
Partnered analytics
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- VERIFIED ACTIVE 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Debiopharm located?
- Debiopharm operates from Forum apres-demain, Chemin Messidor 5-7, CH-1006 Lausanne, Switzerland, Lausanne, Switzerland.
- Who runs Debiopharm?
- Debiopharm is led by Frédéric Lévy, Chief Executive Officer, Debiopharm International. Verified 14 Mar 2026.
- What does Debiopharm do?
- Debiopharm adds a Swiss oncology-development node with a current official management disclosure and a visible partnering posture. Core capabilities: Oncology Development, Partnered Clinical Strategy, Drug Development Governance.
Editorial context
Related technical briefs
Briefs that name Lausanne as a covered market or city.